Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

78.12 -0.28 (-0.36%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,375,502
Open 77.52
Bid (Size) 78.04 (3)
Ask (Size) 78.40 (5)
Prev. Close 78.40
Today's Range 77.28 - 78.40
52wk Range 57.16 - 89.74
Shares Outstanding 1,253,809,440
Dividend Yield 3.64%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
2 Top Biotech Stocks to Buy in June
Both companies have solid therapy franchises and continue to expand their horizons. 
Via The Motley Fool

Performance

YTD
-8.51%
-8.51%
1 Month
+0.01%
+0.01%
3 Month
-1.74%
-1.74%
6 Month
-11.18%
-11.18%
1 Year
+27.69%
+27.69%

More News

Read More
New Drugs in Fight Against Cancer Being Powered by Novel Mechanisms of Action
Via FinancialNewsMedia
3 Biotech Stocks That Could Skyrocket in the Next 12 Months
Via InvestorPlace
AbTherx Announces License Agreement with Gilead
Via ACCESSWIRE
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Kite’s Tecartus® CAR T-cell Therapy Demonstrates 78% Complete Response Rate and 90% Overall Response Rate in Largest Real-World Evidence Analysis for Relapsed/Refractory Mantle Cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
Trodelvy® Continues to Show Durable Overall Survival Advantage in Pre-Treated HR+/HER2- Metastatic Breast Cancer
From Gilead Sciences, Inc.
Via Business Wire
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
From Gilead Sciences, Inc.
Via Business Wire
ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Crashes
Via Investor's Business Daily
Biotechs Zeroing In on Developing Breakthrough Therapeutics for Metastatic Breast Cancer
Via FinancialNewsMedia
Exposures COVID-19
Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival in Non-Small Cell Lung Cancer Study
From Gilead Sciences, Inc.
Via Business Wire
3 Dividend Stocks You Can Buy Without Any Hesitation
Via The Motley Fool
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Via InvestorPlace
Gilead and Kite Oncology Demonstrate Growing Hematology Pipeline and Strength of Leading Cell Therapy Portfolio at EHA
From Gilead Sciences, Inc.
Via Business Wire
Stocks Going Ex-Dividend In June 2023
Via Talk Markets
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Promising Developments Announced Ahead of 2023 ASCO Annual Meeting’s Oral Presentations
Via FinancialNewsMedia
Exposures Product Safety
Arcus Biosciences Soars On Roche's 'Meaningful' Results In A New Cancer Drug Class
Via Investor's Business Daily
CHMP Adopts Positive Opinion to Extend the Use of Veklury® (Remdesivir) to Treat COVID-19 in People With Severe Renal Impairment, Including Those on Dialysis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Stock Reaches 80-Plus Relative Strength Rating Benchmark
Via Investor's Business Daily
3 Relatively Safe Stocks to Buy if a Recession Is on the Way
Via The Motley Fool
Vertex Pharmaceuticals Hits Record High on Strong Q1 Earnings
Via MarketBeat
Exposures Product Safety
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.